A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Condition: Diabetic Gastroparesis Interventions: Drug: CIN-102 Dose 1; Drug: CIN-102 Dose 2; Drug: Placebo Sponsor: CinDome Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
PTH Attenuation Trial in Hemodialysis-1
Condition: Secondary Hyperparathyroidism Interventions: Drug: PLS240; Drug: Placebo; Drug: Open-Label Extension PLS240 Sponsors: Pathalys Pharma; Launch Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Condition: Diabetic Gastroparesis Interventions: Drug: CIN-102 Dose 1; Drug: CIN-102 Dose 2; Drug: Placebo Sponsor: CinDome Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
PTH Attenuation Trial in Hemodialysis-1
Condition: Secondary Hyperparathyroidism Interventions: Drug: PLS240; Drug: Placebo; Drug: Open-Label Extension PLS240 Sponsors: Pathalys Pharma; Launch Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Condition: Diabetic Gastroparesis Interventions: Drug: CIN-102 Dose 1; Drug: CIN-102 Dose 2; Drug: Placebo Sponsor: CinDome Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
PTH Attenuation Trial in Hemodialysis-1
Condition: Secondary Hyperparathyroidism Interventions: Drug: PLS240; Drug: Placebo; Drug: Open-Label Extension PLS240 Sponsors: Pathalys Pharma; Launch Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Condition: Diabetic Gastroparesis Interventions: Drug: CIN-102 Dose 1; Drug: CIN-102 Dose 2; Drug: Placebo Sponsor: CinDome Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Lilly's Tirzepatide Achieved up to 15.7% Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2
INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. The study met... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 27, 2023 Category: Pharmaceuticals Source Type: clinical trials
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer ’s Disease and Cerebral Amyloid Angiopathy
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer
NATICK, Mass. and QUINCY, Mass., April 26, 2023. Avenge Bio, Inc. ( " Avenge " ), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte Immunotherapy platform for the precision administration of potent immune effector... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
South San Francisco, CA -- April 25, 2023 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that post-hoc data indicate treatment with Vabysmo® (faricimab-svoa) led to greater and faster drying of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
NAARDEN, the Netherlands and MIAMI, April 25, 2023. NewAmsterdam Pharma Company N.V. (“NewAmsterdam Pharma” or the“Company”), a clinical-stage company focused on the research and development of transformative oral... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
MAD Study of NX210c
Condition: Healthy Elderly Interventions: Drug: NX210c; Drug: Placebo Sponsors: Centre for Human Drug Research, Netherlands; Axoltis Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2023 Category: Research Source Type: clinical trials
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Conditions: Parasitemia; Clinical Malaria; Immune Tolerance Interventions: Drug: Dihydroartemisinin; Drug: Piperaquine; Drug: Primaquine; Drug: Momordica Charantia Extract Sponsor: Syamsudin Abdillah,Ph.D, Pharm D Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2023 Category: Research Source Type: clinical trials
